STEER Gives Boost for Horlicks Production, GSK Acknowledges Technology
7.1.2020 09:30:00 EET | Business Wire | Press release
STEER Engineering, creator of advanced materials platform technologies that effectively transform and functionalise materials in the fields of plastics, pharmaceuticals, food & nutraceuticals, biomaterials and biorefining, announced that it has reached an out-of-court settlement with Glaxo Smith Kline Group (GSK) with regard to the use of their revolutionary technology to produce Horlicks.
Following the settlement, GSK has issued a public statement acknowledging STEER’s contribution in creating step change technology to produce Horlicks. GSK said,“Using STEER’s state-of-the-art technology, high quality extruders, and dedicated personnel, the project has brought a new-to-world technology to fruition, involving numerous improvements compared to the traditional way Horlicks is made. The new process requires only half the footprint of a traditional factory, uses a fifth of the water and reduces the energy usage by 80%.”
Stating that the two companies have reached a satisfactory settlement, the Managing Director of STEER, Dr. Babu Padmanabhan said, “There is no other technology available in the market that has this immense cost benefit and extraordinary performance. Apart from Horlicks, the technology can be used for the manufacture of other food ingredients. STEER will continue to remain focused on supporting India’s quest in bridging the nutrition gap and help ensure food supply-demand stability.”
It may be recalled that in December 2018, STEER had gone to court seeking protection of the technology and know-how it had provided to GlaxoSmithKline Group (GSK) for manufacture of Horlicks, after GSK announced the deal with Hindustan Unilever Limited for its Consumer Healthcare business in India, leading to IP issues which have been settled.
About STEER
STEER is a creator of advanced material platform / manufacturing technologies that transform functionality of differentiated plastics, pharmaceuticals, food & nutraceuticals and biomaterials. Founded in 1993 by Dr. Babu Padmanabhan with a vision to “steer a new world” – a world that is healthy and sustainable, STEER today has 5 global offices and 10 satellite offices, serving over 39 countries and employs over 500 gifted engineers, scientists and technicians across the globe. With 60 patents for breakthrough innovations, the company is committed to the design, creation and implementation of game-changing continuous process technologies.
- Linkedin: https://www.linkedin.com/company/14623159
- Twitter: @STEER_Official
- Facebook: https://www.facebook.com/STEERWorld/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005566/en/
Contact information
Amit Jain, Equator Consultants
amit@equatormpr.com
+919886062866
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 16:00:00 EEST | Press release
The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support the Olympic Movement and sport around the world. JPMorganChase’s global reach and expertise will
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 16:00:00 EEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin ® Delivery System for Overactive Bladder28.4.2026 15:42:00 EEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 15:28:00 EEST | Press release
CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 15:11:00 EEST | Press release
BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427537841/en/ Thomas Coesfeld and Bob Valentine, Courtesy of BMG and Concord The combination comes amid significant transformation in the global music market, where scale, global reach, and technology investment are increasingly critical to remain competitive. Together, BMG and Concord will form a fully integrated global music company spanning music publishing, recorded music, theatrical rights, and digital distribution. This increased scale will enable deeper investment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
